Analysis of sugammadex for antagonistic neuromuscular block in patients with radical resection of lung cancer under thoracoscope

• Published in: Zhong hua yi xue za zhi Vol. 100; no. 3; p. 213
• Main Authors: Ba, Y F, Liu, Y N, He, S H, Li, H M, Wang, H R, Zhu, J P, Xing, W Q, Li, C S
• Format: Journal Article
• Language: Chinese
• Published: China 21.01.2020
• Subjects: Androstanols - administration & dosage; Androstanols - antagonists & inhibitors; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Lung Neoplasms - pathology; Lung Neoplasms - surgery; Neostigmine - administration & dosage; Neuromuscular Blockade - methods; Neuromuscular Nondepolarizing Agents - administration & dosage; Neuromuscular Nondepolarizing Agents - adverse effects; Sugammadex - administration & dosage; Sugammadex - adverse effects; Thoracoscopes; Neuromuscular blockade; Hemodynamics; Sugammadex; Lung neoplasms
• ISSN: 0376-2491
• DOI: 10.3760/cma.j.issn.0376-2491.2020.03.011

To investigate the efficacy and safety of sugammadex for antagonistic neuromuscular block in patients with radical resection of lung cancer under thoracoscope. One hundred patients undergoing radical resection of lung cancer under thoracoscope in Affiliated Cancer Hospital of Zhengzhou University from March to September in 2019, were randomly divided into control group (group C) and sugammadex group (group S). All patients were anaesthetized (induced and maintained) with intravenous target-controlled infusion of propofol and remifentanil, and intermittent intravenous injection of the neuromuscular block of rocuronium. During the operation, the bispectral index (BIS) was used to monitor the depth of anesthesia, and the neuromuscular block was assessed with TOF. Single-lung mechanical ventilation and double-lumen endotracheal intubation were carried out, and patient-controlled analgesia after operation were enforced. Patients in group C received neostigmine (2 mg) combined with atropine (0.5-1.0 mg) after thora